Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide prevention of post-transplant diabetes in immediate kidney transplant recipients
2023-506437-29-00Phase 3Authorised
- Sponsor
- Bellvitge University Hospital
- Start
- Dec 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of dulaglutide in post-transplantation diabetes mellitus (PTDM) and prediabetes (2 arms), sponsored by Bellvitge University Hospital. Planned start Dec 2023; status: authorised.
02
Drugs
dulaglutide
03
Conditions
post-transplantation diabetes mellitus (PTDM)prediabetes
Beyond the preview
Go deeper on 2023-506437-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506437-29-00.